In response to blistering criticism, the Food and Drug Administration committed to publicly disclosing reviews of scientific data and other information that are used to authorize, revise or revoke emergency use of a medicine.
The announcement came the same day that the U.S. Government Accountability Office issued a report noting the agency has failed to “uniformly disclose its scientific review of safety and effectiveness data” for emergency use authorization as it does for medicines undergoing the normal review process.
About the Author Reprints
